Cost-Effectiveness Analysis of 68Ga-DOTATATE PET/MRI in Radiotherapy Planning in Patients with Intermediate-Risk Meningioma.

BACKGROUND AND PURPOSE While contrast-enhanced MR imaging is the criterion standard in meningioma diagnosis and treatment response assessment, gallium 68Ga-DOTATATE PET/MR imaging has increasingly demonstrated utility in meningioma diagnosis and management. Integrating 68Ga-DOTATATE PET/MR imaging in postsurgical radiation planning reduces the planning target volume and organ-at-risk dose. However, 68Ga-DOTATATE PET/MR imaging is not widely implemented in clinical practice due to higher perceived costs. Our study analyzes the cost-effectiveness of 68Ga-DOTATATE PET/MR imaging for postresection radiation therapy planning in patients with intermediate-risk meningioma. MATERIALS AND METHODS We developed a decision-analytical model based on both recommended guidelines on meningioma management and our institutional experience. Markov models were implemented to estimate quality-adjusted life-years (QALY). Cost-effectiveness analyses with willingness-to-pay thresholds of $50,000/QALY and $100,000/QALY were performed from a societal perspective. Sensitivity analyses were conducted to validate the results. Model input values were based on published literature. RESULTS The cost-effectiveness results demonstrated that 68Ga-DOTATATE PET/MR imaging yields higher QALY (5.47 versus 5.05) at a higher cost ($404,260 versus $395,535) compared with MR imaging alone. The incremental cost-effectiveness ratio analysis determined that 68Ga-DOTATATE PET/MR imaging is cost-effective at a willingness to pay of $50,000/QALY and $100,000/QALY. Furthermore, sensitivity analyses showed that 68Ga-DOTATATE PET/MR imaging is cost-effective at $50,000/QALY ($100,000/QALY) for specificity and sensitivity values above 76% (58%) and 53% (44%), respectively. CONCLUSIONS 68Ga-DOTATATE PET/MR imaging as an adjunct imaging technique is cost-effective in postoperative treatment planning in patients with meningiomas. Most important, the model results show that the sensitivity and specificity cost-effective thresholds of 68Ga-DOTATATE PET/MR imaging could be attained in clinical practice.

[1]  J. Barnholtz-Sloan,et al.  CBTRUS Statistical Report: Pediatric Brain Tumor Foundation Childhood and Adolescent Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014-2018. , 2022, Neuro-oncology.

[2]  C.-C. Jay Kuo,et al.  Incidence trends and survival analysis of atypical meningiomas: a population-based study from 2004 to 2018 , 2022, Journal of Neuro-Oncology.

[3]  M. Mehta,et al.  68Ga-DOTATATE PET: The Future of Meningioma Treatment. , 2022, International journal of radiation oncology, biology, physics.

[4]  M. Berger,et al.  Meningioma DNA methylation groups identify biological drivers and therapeutic vulnerabilities , 2022, Nature Genetics.

[5]  T. Schwartz,et al.  Evaluating diagnostic accuracy and determining optimal diagnostic thresholds of different approaches to [68Ga]-DOTATATE PET/MRI analysis in patients with meningioma , 2021, Scientific Reports.

[6]  Mark W. Youngblood,et al.  Targeted gene expression profiling predicts meningioma outcomes and radiotherapy responses , 2021, Research square.

[7]  David C. Jones,et al.  Integrated Molecular-Morphologic Meningioma Classification: A Multicenter Retrospective Analysis, Retrospectively and Prospectively Validated , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Lydia Y. Liu,et al.  A clinically applicable integrative molecular classification of meningiomas , 2021, Nature.

[9]  Wengen Chen,et al.  68Ga-DOTATATE PET-CT as a tool for radiation planning and evaluating treatment responses in the clinical management of meningiomas , 2021, Radiation Oncology.

[10]  G. Reifenberger,et al.  The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. , 2021, Neuro-oncology.

[11]  M. Weller,et al.  EANO guideline on the diagnosis and management of meningiomas. , 2021, Neuro-oncology.

[12]  C. Auernhammer,et al.  Cost-Effectiveness Analysis of 68Ga DOTA-TATE PET/CT, 111In-Pentetreotide SPECT/CT and CT for Diagnostic Workup of Neuroendocrine Tumors , 2021, Diagnostics.

[13]  T. Schwartz,et al.  Outcomes following upfront radiation versus monitoring in atypical meningiomas: 16-year experience at a tertiary medical center , 2021, Neuro-oncology advances.

[14]  S. Nehmeh,et al.  Dynamic 68Ga-DOTATATE PET/MRI in the Diagnosis and Management of Intracranial Meningiomas , 2020 .

[15]  D. Ramanathan,et al.  Review of Atypical and Anaplastic Meningiomas: Classification, Molecular Biology, and Management , 2020, Frontiers in Oncology.

[16]  P. Stieg,et al.  [68Ga]-DOTATATE PET/MRI as an adjunct imaging modality for radiation treatment planning of meningiomas , 2020, Neuro-oncology advances.

[17]  E. Arias,et al.  United States Life Tables, 2018. , 2020, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.

[18]  J. Knisely,et al.  Somatostatin receptor-2 negative meningioma: pathologic correlation and imaging implications. , 2020, Clinical imaging.

[19]  M. McDermott,et al.  Surgical outcomes after reoperation for recurrent non-skull base meningiomas. , 2019, Journal of neurosurgery.

[20]  T. Schwartz,et al.  Gallium‐68 DOTATATE PET in the Evaluation of Intracranial Meningiomas , 2019, Journal of Neuroimaging.

[21]  M. McDermott,et al.  Surgical outcomes after reoperation for recurrent skull base meningiomas. , 2019, Journal of neurosurgery.

[22]  N. Albert,et al.  Recurrence pattern analysis after [68Ga]-DOTATATE-PET/CT -planned radiotherapy of high-grade meningiomas , 2018, Radiation oncology.

[23]  M. Reiser,et al.  Cost-effectiveness of Endovascular Therapy for Acute Ischemic Stroke: A Systematic Review of the Impact of Patient Age. , 2018, Radiology.

[24]  D. Owens,et al.  Cost-effectiveness of radiation and chemotherapy for high-risk low-grade glioma , 2017, Neuro-oncology.

[25]  A. Laxton,et al.  Early or late radiotherapy following gross or subtotal resection for atypical meningiomas: Clinical outcomes and local control , 2017, Journal of Clinical Neuroscience.

[26]  M. Reiser,et al.  Improved Detection of Transosseous Meningiomas Using 68Ga-DOTATATE PET/CT Compared with Contrast-Enhanced MRI , 2017, The Journal of Nuclear Medicine.

[27]  T. Trikalinos,et al.  Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and Medicine. , 2016, JAMA.

[28]  A. Buck,et al.  68Gallium-DOTATATE PET in meningioma: A reliable predictor of tumor growth rate? , 2016, Neuro-oncology.

[29]  Rory K. J. Murphy,et al.  Radiation Therapy for Residual or Recurrent Atypical Meningioma: The Effects of Modality, Timing, and Tumor Pathology on Long-Term Outcomes. , 2016, Neurosurgery.

[30]  D. Brachman,et al.  Intermediate-risk meningioma: initial outcomes from NRG Oncology RTOG 0539. , 2015, Journal of neurosurgery.

[31]  M. Svensson,et al.  The Willingness to Pay for a Quality Adjusted Life Year: A Review of the Empirical Literature. , 2015, Health economics.

[32]  C. Leães,et al.  Expression of somatostatin receptors (SSTR1-SSTR5) in meningiomas and its clinicopathological significance. , 2015, International journal of clinical and experimental pathology.

[33]  N. Samani,et al.  QALYs in cost-effectiveness analysis: an overview for cardiologists , 2015, Heart.

[34]  R. Hicks,et al.  Somatostatin receptor imaging with 68Ga DOTATATE PET/CT: clinical utility, normal patterns, pearls, and pitfalls in interpretation. , 2015, Radiographics : a review publication of the Radiological Society of North America, Inc.

[35]  M. Roethke,et al.  Comparison of ⁶⁸Ga-DOTATOC-PET/CT and PET/MRI hybrid systems in patients with cranial meningioma: Initial results. , 2015, Neuro-oncology.

[36]  Melissa A. Z. Knoll,et al.  Incentivizing Delayed Claiming of Social Security Retirement Benefits Before Reaching the Full Retirement Age , 2014 .

[37]  Joshua T. Cohen,et al.  Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold. , 2014, The New England journal of medicine.

[38]  Joseph A Hill United States Life Tables , 2013 .

[39]  M. Wallander,et al.  Epidemiology of Meningioma in the United Kingdom , 2012, Neuroepidemiology.

[40]  Y. Garces,et al.  Stereotactic radiosurgery of World Health Organization grade II and III intracranial meningiomas , 2012, Cancer.

[41]  I. Steffen,et al.  Magnetic resonance imaging, computed tomography, and 68Ga-DOTATOC positron emission tomography for imaging skull base meningiomas with infracranial extension treated with stereotactic radiotherapy - a case series , 2012, Head & Face Medicine.

[42]  Joseph O. Deasy,et al.  Common Terminology Criteria for Adverse Events (CTCAE) v4.0 Based Hybrid Patient and Physician Questionnaire for Head and Neck (HN) Radiotherapy Symptom Reporting , 2011 .

[43]  S. J. Whitehead,et al.  Health outcomes in economic evaluation: the QALY and utilities. , 2010, British medical bulletin.

[44]  S. Bae,et al.  International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? , 2010, Health economics.

[45]  H. Fernandes,et al.  Meningioma recurrence: The efficacy and cost-effectiveness of current screening , 2010, British journal of neurosurgery.

[46]  W. Curry,et al.  LONG‐TERM RECURRENCE RATES OF ATYPICAL MENINGIOMAS AFTER GROSS TOTAL RESECTION WITH OR WITHOUT POSTOPERATIVE ADJUVANT RADIATION , 2009, Neurosurgery.

[47]  D. Cohen,et al.  Interpreting the results of cost-effectiveness studies. , 2008, Journal of the American College of Cardiology.

[48]  J. Reubi,et al.  Affinity profiles for human somatostatin receptor subtypes SST1–SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use , 2000, European Journal of Nuclear Medicine.

[49]  Mark Payne,et al.  Health and Human Services , 2020, Congress and the Nation 2013-2016, Volume XIV: Politics and Policy in the 113th and 114th Congresses.

[50]  P. Wen,et al.  Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review , 2014 .

[51]  R. Buchert,et al.  Cost comparison of 111In-DTPA-octreotide scintigraphy and 68Ga-DOTATOC PET/CT for staging enteropancreatic neuroendocrine tumours , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[52]  Henry Brem,et al.  Central nervous system cancers: Clinical Practice Guidelines in Oncology. , 2005, Journal of the National Comprehensive Cancer Network : JNCCN.

[53]  R. Martuza,et al.  Meningioma: analysis of recurrence and progression following neurosurgical resection. , 1985, Journal of neurosurgery.